MAGNACHIP SEMICONDUCTOR Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MAGNACHIP SEMICONDUCTOR Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $178.86M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $196.43M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $230.05M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $337.66M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $474.23M | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $142.95M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $124.81M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $118.83M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $120.47M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $123.35M | Mar 9, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.39M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $38.73M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $51.64M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $101.26M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $153.54M | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $38.46M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $28.59M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $32.14M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $29.13M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $30.50M | Mar 9, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.72M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($54.31M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($36.62M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($8.04M) | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $56.71M | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $66.58M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $272.96M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $29.17M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($23.75M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $23.43M | Mar 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.86M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($25.97M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($57.64M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($5.24M) | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $83.41M | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $9.21M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $3.22M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $8.62M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $5.97M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $5.69M | Mar 9, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.30M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $25.01M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $51.56M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $52.34M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $51.21M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $45.70M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $45.02M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $46.04M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $70.52M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $72.18M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.12M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $38.10M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $48.47M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $50.87M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $52.44M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $49.97M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $47.60M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $47.71M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $81.78M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $83.55M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.21M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($6.13M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($3.01M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $5.17M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $87.74M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $7.47M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $50.50M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $39.24M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($20.25M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $9.37M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.99M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $11.60M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $6.96M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $23.39M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $32.21M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $36.10M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $22.96M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $28.95M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $32.66M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $18.73M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $351.53M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $379.32M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $420.49M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $516.65M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $583.65M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $571.69M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $595.33M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $583.20M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $558.79M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $441.95M | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.28M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $102.52M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $75.89M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $88.49M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $130.89M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $226.09M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $610.31M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $600.51M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $598.43M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $514.07M | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $248.25M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $276.80M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $344.60M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $428.15M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $452.76M | Mar 8, 2024 |
| FY2023 | Dec 31, 2020 | $345.60M | Mar 8, 2024 |
| FY2022 | Dec 31, 2019 | ($14.98M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | ($17.31M) | Feb 23, 2022 |
| FY2019 | Jan 1, 2018 | $8.48M | Feb 21, 2020 |
| FY2020 | Dec 31, 2017 | ($39.64M) | Mar 9, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2012 | $3.36M | Feb 12, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.85M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $244.58M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $298.88M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $335.51M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $343.54M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $286.83M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($58.13M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2018 | $8.48M | Mar 9, 2021 |
| FY2018 | Dec 31, 2017 | ($40.89M) | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | ($125.83M) | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.76M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $138.61M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $158.09M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $225.48M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $279.55M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $279.94M | Feb 23, 2022 |
| FY2021 | Dec 31, 2019 | $151.66M | Feb 23, 2022 |
| FY2021 | Dec 31, 2018 | $132.44M | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | $128.58M | Mar 9, 2021 |
| FY2019 | Dec 31, 2016 | $101.61M | Feb 21, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $83.48M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $304.74M | Mar 9, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | 1 | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | 7 | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | 1 | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | 5 | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36.22M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 36.91M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 38.85M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 43.82M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 45.66M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 35.78M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 34.80M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 34.44M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 34.19M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 35.05M | Feb 22, 2018 |